AbbVie inks $700M deal with IGI for multiple myeloma trispecific antibody
AbbVie will spend $700 million upfront, plus future payments, on a trispecific antibody for blood cancer from IGI Therapeutics, adding to a slow but steady …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.